Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001366200 | SCV001562496 | likely pathogenic | Familial hypercholesterolemia | 2022-11-29 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 1057254). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Asp227 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17539906, 19467224, 21310417, 21382890, 22883975, 23375686, 23669246, 27680772). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. This variant has not been reported in the literature in individuals affected with LDLR-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 227 of the LDLR protein (p.Asp227His). |
| All of Us Research Program, |
RCV004006797 | SCV004832944 | uncertain significance | Hypercholesterolemia, familial, 1 | 2023-04-27 | criteria provided, single submitter | clinical testing |